Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.
Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. Thus, only 50-60% of patients with multiple myeloma or non-Hodgkin lymphoma respond to ESAs. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.
Study Type
OBSERVATIONAL
Enrollment
30
Laval Hospital
Laval, France
Rennes University Hospital
Rennes, France
Yves Le Foll Hospital
Saint-Brieuc, France
Saint-Malo Hospital
St-Malo, France
Bretagne Atlantic Hospital
Vannes, France
response to erythropoietin
* Complete response : increase of 2g/dl of erythropoietin rate or stopping of transfusion requirements. * Partial response : increase of 1 to 2g/dl rate of erythropoietin or 50% reduction of transfusion requirements.
Time frame: 12 weeks
endogenous erythropoietin rate
Time frame: Within 8 days before inclusion
hemoglobin rate
Weeks 0 = first ESAs injection
Time frame: Weeks 0,4,8 and 12
Number of transfusions during the duration of the study
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.